首页> 美国卫生研究院文献>Neurotherapeutics >Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients with Rheumatoid Arthritis?

【2h】

Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients with Rheumatoid Arthritis?

机译：疾病改性抗风湿药物可降低类风湿性关节炎患者发育痴呆症的风险吗？

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Demographic data between the non-RA and RA groups (n = 82,828)

机译：非RA和RA组之间的人口统计数据（n = 82,828）

著录项

期刊名称 Neurotherapeutics
作者
Ling-Chun Huang; Yu-Han Chang; Yuan-Han Yang;
展开▼
作者单位

展开▼
年(卷),期 2019(16),3
年度 2019
页码 703–709
总页数 7
原文格式 PDF
正文语种
中图分类神经科学;药学;神经病学;
关键词

机译：疾病改性抗风湿性药物;痴呆;炎症;类风湿性关节炎;

相似文献

外文文献
中文文献
专利

1. Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a post hoc multicohort analysis [J] . Ahmad Y. Abuhelwa, David J. R. Foster, Arkady Manning-Bennett, Therapeutic advances in musculoskeletal disease. . 2021,第a期

机译：伴随的β-受体阻滞剂使用与用疾病改性抗风湿药物治疗的类风湿性关节炎患者的缓解率降低：后HOC多型型分析
2. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial [J] . KurasawaT., NagasawaH., KishimotoM., Modern rheumatology . 2014,第4期

机译：甲氨蝶呤中添加另一种疾病改良抗风湿药可降低英夫利昔单抗类风湿关节炎患者停用后2年内的眩晕率：一项开放，随机，对照试验
3. Addition of another disease-modifying anti-rheumatic drug to methotrexate reduces the flare rate within 2 years after infliximab discontinuation in patients with rheumatoid arthritis: An open, randomized, controlled trial [J] . Kurasawa Takahiko, Nagasawa Hayato, Kishimoto Mayumi, Modern rheumatology . 2014,第4期

机译：甲氨蝶呤中添加另一种疾病改良抗风湿药可降低英夫利昔单抗类风湿关节炎患者停用后2年内的眩晕率：一项开放，随机，对照试验
4. New candidate parameters for evaluation of cardiovascular risk in patients with rheumatoid arthritis [C] . V. O. Omelchenko, M. A. Korolev, E. A. Letyagina, 2017 International Multi-Conference on Engineering, Computer and Information Sciences . 2017

机译：类风湿关节炎心血管风险评估的新候选参数
5. The Efficacy of Therapeutic Drug Monitoring of Rheumatoid Arthritis Patients on Infliximab [D] . Abolhosn, Rania. 2018

机译：类风湿性关节炎患者治疗药物监测对英夫利昔单抗的疗效
6. Concomitant beta-blocker use is associated with a reduced rate of remission in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs: a [O] . Ahmad Y. Abuhelwa, David J. R. Foster, Arkady Manning-Bennett, 2021

机译：伴随的β-阻滞剂使用与用疾病改性抗风湿药物治疗的类风湿性关节炎患者的缓解率降低有关：a
7. AB0426 COMPARISON OF INFLUENCES OF DIFFERENT CONCOMITANT DRUGS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH IGURATIMOD, A CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUG DEVELOPED IN JAPAN, IN REAL-WORLD CLINICAL SETTING [O] . Yuji Hirano, Daisuke Kihira, Yukiyoshi Oishi 2019

机译：AB0426在现实世界临床环境中，在Iguratimod治疗IGURATIMOD治疗的类风湿性关节炎患者中不同伴随药物对类风湿性关节炎患者的影响

Can Disease-Modifying Anti-Rheumatic Drugs Reduce the Risk of Developing Dementia in Patients with Rheumatoid Arthritis?

摘要

著录项

相似文献

相关主题

期刊订阅